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ABSTRACT
E. coli is the most frequently isolated Gram negative pathogen from bacteremia in cancer
patients and is repeatedly recovered from many other extraintestinal illnesses. These infections
are commonly endogenous in nature and interfere with the treatment of cancer resulting in
increased healthcare costs, morbidity, and mortality rates. Cancer and the treatments related to
cancer cause alterations in the microbiome of the gut and other organs. Despite this point, there
is a serious lack of knowledge about the genetic types of E. coli infecting cancer patients. This
gap results in vague prevention strategies and limited treatment options for cancer patients.
Multi Locus Sequence Typing (MLST) was used to successfully genotype 105 sequentially
collected E. coli isolates from patients admitted to H. Lee Moffitt Cancer Center (HLMCC,
Tampa, FL) with confirmed extraintestinal infections between 2010 and 2012. In total, 24
distinct genotypes (STs) have been identified in this dataset using EcMLST (STEC Reference
Center). Of these, ST34 constituted 39% of the sample and may represent a disseminating clone
at HLMCC. Furthermore, 17 isolates not found in the EcMLST database have been identified.
Importantly, phylogenetic analysis of DNA sequence data for MLMCC E. coli revealed only
22% of HLMCC E. coli clustered with ECOR reference strains commonly attributed to the B2
phylogroup of extraintestinal pathogenic E. coli (ExPEC). Four HLMCC E. coli belonging to
ST171 and attributed to life-threatening blood infections clustered with Shiga toxin (Stx)
producing E. coli (STEC) strain TW06296. HLMCC E. coli belonging to ST34 clustered with
enteroaggregative E. coli (EAEC) strain TW10263. Importantly, these non-B2 phylogroup
strains demonstrated more pathogenic potential than HLMCC E. coli clustered with B2 ExPEC,
v

which included a higher incidence of bacteremia and sepsis, as well as resistance to first-line
antibiotics. Upon further investigation, ST34 may equate to ST131 by another MLST database.
These findings suggest that isolates previously characterized as commensal and

intestinal

pathogenic E. coli have an increased ability to cause infection outside of the gastrointestinal tract
in cancer patients and that selective pressures are contributing to increased antibiotic resistance.
These findings may change the approach to clinical management of E. coli infections at cancer
centers.
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CHAPTER ONE:
CANCER AND INFECTION: CONSEQUENCES OF THE IMMUNOCOMPROMISED
IMMUNE SYSTEM AND SUSCEPTIBILITY TO INFECTION

Cancer- Overview
Cancer is an expansive term for many diseases in which abnormal cells uncontrollably divide
and spread. As a leading cause of morbidity and mortality, it warrants serious investigation and
intervention of global concern.

In 2012, cancer plagued 14 million people worldwide.

Furthermore, over 8 million deaths were attributed to cancer and more than 32 million people
diagnosed in the past 5 years are living with the cancer diagnosis (5 year prevalence) (1, 2).
In healthy organisms, abnormal cells are controlled by induction of apoptosis through tumor
suppressor genes. In cancer, mutations in these and other genes results in repression of apoptosis
and subsequent proliferation of atypical cells. Rapidly dividing cancer cells initially cause
tumors in a primary tissue source. Then cells can invade nearby tissue resulting in cancer of
surrounding areas. Additionally, invasion into the circulatory system is the vehicle by which
malignant cells metastasize. Metastasis catapults malignant cells through the circulatory system
which allows for invasion of multiple distant tissues (3).
Although incidence rates vary among cancer type and geographical region, the average rate for
men in 2012 was 205 per 100,000 ranging from as low as 79 per 100,000 in Western Africa, to
1

as high as 365 per 100,000 males in the region of Australia and New Zealand, due to significant
prostate cancer diagnoses.

Women tend to have lower incidence rates, averaging 165 per

100,000 and ranging from 103 per 100,000 in South-Central Asia to 295 per 100,000 women in
Northern America (1).

Unfortunately, many of these diagnoses occur in considerably less

developed regions where the burden of cancer and treatment is even more agonizing. It was
estimated that nearly 8 million new cases, 5.3 million deaths and 15.6 million patients with 5
year prevalence diagnoses occurred in less developed regions in 2012. These regions have
decreased access to prevention, diagnosis and treatment (4). Non-fatal health outcomes are
another concern when considering the overall effects of cancer on a community. In 2010 an
estimated 7.6% of global burden of disease was attributed to neoplasms (5).
Regrettably, the causes of cancer are just as innumerable as the cancers themselves. Although
instances of cancer have been documented as far back as ancient history, the multiple origins of
cancer are still under investigation. Analysis of cancer biology and genetics has allowed us to
understand specific processes, like DNA repair deficits, errors in DNA replication and alterations
in chromosomes, which result in malignancy.

However, the influencers that lead to these

problems are largely unspecific. A few known stimuli include genetic chromosomal mutations,
inflammation, radiation, chemicals and viruses (6).
This broad generalization of cancer, which impacts the lives of millions of people, is well
studied. According to the National Cancer Institute, the United States spends an average of $4.9
billion in research each year. Although great strides have been made in the area of cancer
research, its variability is still perplexing. Midst the many fields of exploration, advances in the
differentiation of malignant cells have helped to determine type, treatment, and response. Cancer
can be categorized according to the location or cell type from where the proliferation of
2

malignant cells originated. According to the National Cancer Institute, there are over one
hundred different types of cancer. However, in most instances all of these can be assembled into
five major categories which include: carcinoma, leukemia, lymphoma and myeloma, sarcoma,
and central nervous system cancers (3).
Carcinoma
Carcinoma makes up the overwhelming majority of illness, surgery, and death by cancer
worldwide.

Carcinoma originates in one of the many types of epithelial cells. The most

common cell types seen in this disease include glandular, basal cells, squamous cells, and
transitional cells (3). Basal epithelial cells line the outermost layer of the epidermis. As such,
they are most frequently found on body parts likely damaged by exposure to UV sunlight and are
therefore the most abundant form of skin cancer (3). Squamous cell carcinomas (SCC) also
account for approximately 700,000 cases of skin cancer in the United States annually (7).
Together, these Non-Melanoma Skin Cancers (NMSCs) are the leading cause of cancer in the
United States and they are increasing. Between 1992 and 2006 NMSCs treatments increased by
a striking 77 percent and they account for an estimated 3.5 million diagnoses every year in the
United States (8). Approximately 90% of NMSC diagnoses are associated with UV sunlight
radiation (9). Additionally, recent increases in indoor tanning have played a role in the increase
of NMSCs. An outsized analysis of non-melanoma skin cancer, comparing use of indoor tanning
and the absence of indoor tanning, calculated a relative risk for SCC and BCC of 1.67 and 1.29
respectively, alluding to a contribution of 170,000 cases of NMSC by indoor tanning each year
(10).
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Squamous cell carcinoma can invade considerably more than the superficial layers of the skin.
Squamous cells also line the respiratory tract, digestive tract, and hollow organs. Squamous cell
carcinomas include cancers that originate in the anus, cervix, head and neck, and vagina.
Transitional cell carcinoma presents in similar sites, as transitional cells line the hollow organs of
the body as well (3). According to 2012 global estimations, with the exclusion of non-melanoma
skin cancer, cervical cancer was the fifth leading cause of cancer in women and accounted for
7.5% of cancer deaths in the female population (1). The majority of cervical cancer cases are
associated with the Human Papillomavirus (HPV) (11). Furthermore, women infected with HPV
who smoke or are exposed to smoke have an even greater risk of developing cervical cancer
(12). Contrarily, cervical cancer in the United States is much lower with 12,340 (0.7%) newly
diagnosed cases and just over 4 thousand deaths.

This decline is attributed to regular

Papanicolaou and HPV screenings as well as the HPV vaccine (13, 14).
Glandular cells are designed to secrete fluids like mucus, digestive enzymes, and milk.
Adenocarcinoma is the resulting cancer from mutations and proliferation of these cells which
accounts for most breast, pancreas, lung, prostate and colon cancers(3). In 2012, lung cancer
alone accounted for an estimated 13% of new cancer diagnoses, a notable 19.4% of cancer
mortalities and 5.8% of patients living with a five year prevalence (1, 2). Lung cancer claimed
over a million lives, making it the leading cause of cancer mortality (1). This substantial death
rate is attributed to smoking, as there are more than 60 carcinogens found in cigarette smoke.
These carcinogens alter the tissue barrier that protects the lungs from multiple environmental
challenges thus resulting in increased bronchial epithelial permeability (15). The risk ratio for
lung cancer is greater than 6 when comparing smokers to non-smokers (16). This is of no
surprise considering mutagens in tobacco smoke modify DNA.

Studies suggest that
4

transcription-coupled repair pathways as well as expression-linked repair pathways are changed
in lung cancer cells (17).
Breast cancer held the second highest estimated incidence rating of 11.9% with a mortality rate
of 6.4% and a five year prevalence of 19.2% (1, 2).

Breast cancer is frequently seen when

mutations have occurred in specific tumor suppressor genes. For example, women with inherited
mutations in BRACA1 and BRACA2 and to a lesser extent, PTEN and TP53, are at a much
greater risk for developing breast cancer (18). These mutations are not the cause of cancer itself
but they are indicative of the patient inability to defend against malignancy in glandular
carcinomas. Rather, extensive research in various mutations seems to suggest that multiple
acquired mutations are to blame for most breast cancers (19-21). These mutations can be caused
by environmental factors like radiation, carcinogen exposure, and other unknown risk factors.
Detection of specific acquired mutations, like multiple copies of HER2, may help to determine
the aggressiveness of treatment therapy and predict patient outcomes to various types of
chemotherapeutic drugs (22-24).
Prostate cancer is the second leading cancer diagnosis for men worldwide. Prostate cancer
accounted for 7.9% of all cancer incidence rates in 2012 and 3.7% of cancer mortalities.
Furthermore, currently over three million men have a 5 year prevalence of prostate cancer.
However, the frequency of prostate cancer between racial backgrounds is divergent. In Western
countries, this is the leading cancer diagnosis for men (1, 2). The highest rates are among
African American men in the United States. This population has a 60% higher incidence rate
than Caucasians with 116 per 100,000 men being diagnosed. Chinese men on the other hand
have a prevalence of only 28 per 100,000 (25). The varying severity of prostate cancer is also a
conundrum. Many cases remain asymptomatic while others result in death. Epidemiological
5

studies support an inherited component to increased risk for prostate cancer. Familial clustering
associations were much stronger than age or race matched control groups. Additionally these
heredity patterns appear more robust than the heredity patterns seen in breast and colon cancers
(26). Other reasons for the differences in potency may include therapy, slow tumor growth or
progression before diagnosis (27). Genome-wide studies suggest both numerous variants and
common patterns implying both genetic and environment factors (28).
In 2012, colorectal cancer (CRC) accounted for 9.7% of new cancer cases, 8.5% of cancer
mortalities and 10.9% of patients with a 5 year prevalence rating. Rates are consistently higher
among men than women and in western countries but show no significant differences between
more or less developed regions (1, 2). Although, the majority of colorectal cancer cases are
considered random, studies suggest that an individual or familial history of non-neoplastic
polyps may increase risk (29-31). This may be an innate or acquired tendency for tumor
formation in the colon which may or may not undergo malignant transformation. Comparisons
of genetic alterations in normal and malignant colon epithelium suggest that the transformation is
a result of multiple acquired molecular events that result in chromosomal instability (32-34).
Sequencing of CRC genes established an average of 90 mutant genes.

69 of those were

considered relevant to pathogenesis of colorectal cancer and an average of nine mutant genes
were seen per tumor (35). A plethora of mutations in DNA damage repair genes and the DNA
mismatch repair system allow for more rapid mutations in cancer-associated genes (36).
These four leading glandular cancers account for over 38% of the estimated cancer deaths in
2012. Although stomach and liver cancer do not retain as high of an incidence rate, their high
mortality rates of 8.8% and 9.1% respectively also contribute greatly to the burden of mortality
by carcinoma (1). Altogether the above cancers account for almost 56% of all cancer mortalities
6

excluding non-melanoma skin cancer in 2012. In other words, they were the cause of over 4.5
million deaths (1).
Leukemia
Leukemia is hematological cancer that starts in the blood-forming tissue, bone marrow, and
spreads through the body by way of the circulatory system. There were over 350,000 new
diagnoses of leukemia in 2013 and over 265,000 deaths. These hematological cancers are
differentiated by rapacity of onset and the cell line from which they originated. This includes
either myeloid or lymphoid stem cell lines and these are further delineated by acute or chronic
onset of disease. Men have higher incidence than women and Caucasians have higher rates than
any other ethnic group (3). The treatment of leukemia generally requires induction therapy
which results in prolonged neutropenia and a high risk of infection.
Leukemia is the most common cancer in children, acute lymphoid leukemia (ALL) being the
most abundant. Innovations in treatment have drastically impacted childhood cure rates which
are now greater than 80% (37). However, ALL accounts for 20% of all acute leukemia in
patients over 20 whose long-term disease free survival is only 30-40% (38). This is a result of
the high frequency of diverse genetic abnormalities in cancer cells, a greater severity of toxicity
from chemotherapy and higher incidence of comorbidities (39). Infections remain the main
causes of morbidity and mortality in ALL patients due to induction chemotherapy and reduced
bactericidal activity of neutrophils (40, 41).

While innovation in treatments allows for a

decrease in mortality rates, increases in diagnosis are seen each year (39).
Various factors play a role in each of the different types of leukemia. Chronic myelogenous
leukemia (CML) patients possess a DNA translocation called the Philadelphia chromosome
7

which results in excess enzymatic production of tyrosine kinase resulting in undue production of
incompetent white blood cells.

This same translocation is occasionally seen in acute

myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) (3). Various other gene
fusions, chromosomal rearrangements, and translocations are contributing factors to these
hematological cancers (42, 43).
Lymphoma and Myeloma
Lymphomas are neoplastic diseases that originate in the lymphatic system. Lymphomas are a
diverse group of diseases as they are the fifth most common group of cancers in the United
States. Lymphomas  are  divided  into  Hodgkin’s and non-Hodgkin’s  based  on  distinguishing cell
characteristics. Hodgkin’s   lymphoma (HL) presents in the lymph nodes and possesses ReedSternberg  cells.    Hodgkin’s  lymphoma  is  a  result  of  acquired  DNA  damage  to  lymphocytes  and  
is currently one of the most curable cancer types. Non-Hodgkin’s   lymphoma   (NHL)   is   much  
more diverse and can vary by aggressive or indolent growth. According to the WHO there are
over 60 sub-types of NHL. Due to these dissimilarities, treatment and survival rates for NHL are
inconsistent.

In 2012, incidence of   Hodgkin’s   lymphoma   were almost 66,000 while non-

Hodgkin’s accounted for almost 386,000 globally (1, 44-46).
Myeloma is another hematological cancer which is commonly referred to as multiple myeloma
(MM). MM affects lymphocytes of B cell lineage resulting in over proliferation of malignant
plasma cells. Plasma cells are responsible for immune protection via antibody production.
Furthermore, they maintain integrity of bones by production of osteoclast activating factor.
Myeloma cells then cluster in the bone marrow and cause a cascade of immune breakdown.
Symptoms of the disease include bone lesions due to rapid growth of myeloma cells,
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hyperkalemia and renal failure due to abnormal proteins, M proteins, deposited for filtration.
Abnormal proteins found in the urine known as Bence Jones protein are another manifestation of
MM. Anemia is commonly seen in MM as well resulting from a decrease in normal bone
marrow cell production. These patients have increased risk for infection because they are
lacking in functional antibodies. The median survival is between 3 and 4 years. MM is twice as
common in African Americans in comparison to European-Americans and is also more common
in men (47, 48).
Sarcoma
Sarcomas are of mesodermal origin which includes connective or supportive tissues. These
tissues include bone, cartilage, fat, striated muscle, and blood vessels. When malignancy is
exclusive to bone it is termed osteosarcoma. Malignancy in bone and soft tissue is Ewing
sarcoma. Although sarcomas are considerably rare, they predominately affect children and
adolescents. Estimations suggest that less than 15,000 Americans will develop this form of
cancer each year. There is currently no link to heredity of this disease and most instances can be
attributed to a translocation of chromosomes. Ironically, the only other known risk factor for the
disease is radiation therapy which is used to treat certain cancers
Central Nervous System Cancers
Central nervous system cancers predominantly begin sporadically in the tissues of the brain and
spinal cord (CNS). An estimated 256,000 new cases occur globally, 24,500 of those being in the
United States. Brain tumors are the leading cause of death from CNS cancers and make up 27%
of childhood cancers. An estimated 3,200 children will be diagnosed with this cancer in 2013.
Men are at a higher risk for acquisition and mortality from CNS cancers and Caucasians are
9

more affected than any other racial group (49). Robust associations exist between brain cancer
and specific inherited syndromes in which tumors are frequent, such as neurofibromatosis type 1
and 2, tuberous sclerosis, von Hippel Lindau disease and Li Fraumeni, Gorlin and Turcot
syndromes (50).

Secondly, exposure to carcinogenic compounds found in occupational

environments may play a role in CNS and brain cancers (51, 52).
Clearly the abundance of cancers and the multifactorial origins of cancer are more complex than
we have managed to cover in this text or in the current medical community. Furthermore, the
secondary effects on patients treated for these terrible diseases raise ongoing questions regarding
the impact of current treatments on the burden of disease and the severity of treatment related
ailments.
Compromised Host Defense- Cancer and Therapy
The human body has a multitude of protective mechanisms. A healthy individual employs
mostly nonspecific resistance to pathogens continuously through intact skin and mucous
membranes, excretory functions, cilia, microflora, naturally secreted antibodies, complement,
lysozymes and genetic factors.

These initial responses serve to delay or destroy foreign

pathogen invasion while activating specific immune responses. Interruption or overstimulation
of this general reaction results in a targeted response by the immune system (53). The specificity
of this adaptive response varies but it can include white blood cells such as lymphocytes,
phagocytes, and natural-killer cells (54). In cancer patients, immunodeficiency is a common
problem resulting from the disease itself, chemotherapy, and/or radiation therapy. A severe
reduction in the absolute number of neutrophils below normal range, called neutropenia, is a
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frequent result of intensive chemotherapy and radiation. In turn,  the  body’s immunity resistance
is jeopardized to both native organisms and foreign pathogens.
Treatment of cancer often requires impairment of many other natural immune responses. One
major contributing factor to this impairment is breakdown of the integumentary system, the skin
barrier. When kept intact, skin is one of the most important means of infection prevention as it is
impenetrable and even damaging to most harmful pathogens. Any trauma or puncture to the skin
is a risk factor for infection by both endogenous and exogenous microorganisms. Unfortunately,
the treatment of cancer requires disturbance of the skin; the most obvious example being the
removal of a malignant tumor. Cancer patients may also require intravenous medicines, fluids
and nutrition on a continual basis. This medical necessity leaves the patient with a constant
penetration of the skin by a catheter or other indwelling medical device. Invasive medical
devices like endotracheal intubation and mechanical ventilation, are also associated with poor
prognosis in ICU cancer patients to the extent that cancer centers have attempted to use
noninvasive continuous airway pressure in order to avoid the imminent repercussions of severe
pneumonia (55). Even standard monitoring of patient status frequently requires blood draw
which may result in hematoma (56).
Furthermore, skin toxicity, which can present in the forms of rashes, dryness, pruritus,
paronychia, and even hair abnormalities, is a repeatedly documented side effect in cancer
therapeutics (57). For example, solid tumor cancers can be treated with epidermal growth factor
receptor tyrosine kinase inhibitors. Preventing the activation of tyrosine kinase receptors averts
potential increases in tumor cell proliferation and the concurrent affects. Treatment with these
drugs in specific cancers, like metastatic non-small cell lung, seems to fare better than more
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common chemotherapy regimens (58). However, adverse effects of skin toxicity result in more
than 80% of patients (59).
The skin is often the first organ affected in graft-versus-host disease (GVHD).

GVHD is an

immune response of donor T-cells attacking host cells post bone marrow transplant or stem cell
transplant (60).

These visible disruptions of skin from immunological and inflammatory

responses leave the body vulnerable to infection.

Unseen changes resulting from immune

responses include alterations in pH, changes in structure and the ability of the skin to shed. This
modifies the environment of the skin and subsequently changes the colonizers of the skin.
Alterations in the integumentary microbiome can cause nosocomial infections from both
endogenous and exogenous pathogens (61) .
Treatment regimens of chemotherapy and radiation can also disrupt the protective components of
mucosal membranes. Mucositis can occur in the mouth and the GI tract. These cells, like cancer
cells, are rapidly dividing. Consequently, targeted chemotherapy or close proximity radiation
treatment may damage both cancer cells and endometrial cells of the mucosal membrane. This
damage makes normal tissue repair of damaged DNA and cell division challenging.
Normally, secretions from mucous membranes protect the body from invasion of
microorganisms through multiple mechanisms.

Many secretions contain antimicrobial

properties. When IgA is present it prevents pathogen attachment to host cell receptors and
causes agglutination of some microorganisms. Additionally, secretions contain iron binding
proteins that compete with microorganisms for iron (53). The breakdown of these protective
mechanisms results in an imbalance of microorganisms and an exposed surface making invasion
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of both asymptomatic colonizers and pathogenic bacteria, as well as reactivation of viruses, an
easy feat (62).
Moreover, damage to the fibronectin barrier that protects the epithelial cells is a result of ageing
and illness, like the cancer itself. This factor may allow for unsuitable colonization of the
oropharynx with gram-negative bacteria (GNB) instead of the normal gram-positive bacteria.
Colonization then increases the likelihood of pneumonia of GNB origin in cancer patients. One
example indicated a strong correlation, as 23% of colonized GNB intensive care patients
presented with GNB pneumonia while only 3% of non-colonized patients had a GNB pneumonia
infection (63-67).
Normal flora of the gastrointestinal (GI) tract protects against colonization from aerobic
exogenous microbes.

This environment contains over 400 obligate anaerobic species.

In

addition to protection from external organisms, endogenous anaerobes also prevent overgrowth
of common GNB in the GI tract. Antibiotics used to protect neutropenic cancer patients may
disrupt this cantankerous balance which can be deadly, especially when mucous membranes are
disturbed by cancer treatment.

Frequent antibiotic therapy for patients undergoing cancer

treatment can result in destruction of anaerobic bacteria in the gut thus halting the competitive
environment and sanctioning excessive growth of GNB. Once overrun, GNB can then attach and
invade the compromised walls of the GI tract resulting in bacteremia. However, treatments with
antibiotics that do not fight against anaerobic bacteria increase risk of infections like enterocolitis
by overgrowth of anaerobes. The GI tract is notably the most important endogenous source of
GNB found in the body (68-71).

13

Reversely, the urinary tract is a sterile system frequently afflicted by GNB. It is well known that
urinary tract infections are one of the most commonly encountered problems in healthcare. The
immunocompromised immune system, by way of cancer and its treatment, can work in
congruency with catheterization and instrumentation to promote urinary tract infections in cancer
patients even more so. Catheterization can be necessary for cancer patients. Some drugs require
irrigation in order to prevent damage to the bladder. A lack of host defenses like functional
phagocytes and secretory IgG and IgA, along with impeded free flow of urine, adequate bladder
emptying and intact epithelial lining creates a hatchery for entry and proliferation of
microorganisms up the ureters and into the bladder. Furthermore, damage to bladder mucosa by
chemotherapy or instrumentation can also predispose to infections.

Multiple paraneoplasic

syndromes can cause urine stasis by incomplete bladder emptying. Tumors that originate in or
close to the urinary tract, prostatic enlargement, or prostate cancer, can cause an obstructed flow
of urine which may block part of the organ from emptying and allow for overgrowth of
microorganisms. A hyperuricemic state created by hyperkalemia, tumors or the treatment of
tumors may also cause stones in the bladder and obstruct urine flow. Conditions or tumors
involving the spinal cord that cause neurogenic bladder can cause incomplete bladder emptying
and result in infection as well (72).
Currently the most beneficial cancer treatments, like radiation and chemotherapy, are also the
origins by which many patients develop life-threatening infections. Furthermore, use of broadspectrum antibiotics on immunocompromised cancer patients results in selection of resistant
pathogens for infection which in turn results in high mortality. Weakened immunity including
neutropenia, innate immune disruption and altered microflora consequently allow for infections
of bacterial, fungal and viral origin.
14

Infection-Overview
Infections are to blame for approximately half of the deaths in cancer patients (73).

An

immunocompromised patient is susceptible to infection because they are lacking in basic
immune functions. Furthermore, chemotherapy related neutropenia is a serious cause of this
immune deficit in cancer patients; many of whom receive both myelosuppressive and
immunosuppressive drugs. Hence, it is only commonsensical that pretreated patients develop
more infections than untreated cancer patients (74).
Table 1 Microbiology and Patient Morbidity and Mortality According to Klastersky,
et. al., 2007, of 2,142 Febrile Neutropenic Cancer Patients
Total
Complications
Mortality
Bacteraemia
n=499 (23%)*
Single Gram-negative
168 (34%)
38 (23%)
30 (18%)
Single Gram-positive
283 (57%)
57 (20%)
13 (5%)
Polymicrobial
At least one Gram-negative
Only Gram-positive

48 (10%)
29
19

11 (23%)
8
3

6 (13%)
5
1

* Percentage based on total number of febrile neutropenic cancer patients (n=2,142).

Bacteremia is a leading cause of life-threatening infections in cancer patients receiving
chemotherapy (75, 76). In a study of over 2000 neutropenic cancer patients, 23% developed
bacteremia.

Of these, 57% were from Gram-positive organisms, 34% were Gram-negative

organisms and 10% were poly-microbial. These infections resulted in mortality rates of 5%,
18% and 13% respectively, as seen in Table 1 (77). Bacteremia causes higher mortality rates and
increase healthcare costs in cancer patients by delaying chemotherapeutics and prolonging
hospital stays (78, 79).
In order to help prevent bacteremia, physicians develop prophylactic antibiotic regimens to fight
infections before they begin. Cancer patients are predictably neutropenic at specific times of
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treatment. Many infections can be expected based on the antibiotics administered and the length
of neutropenia as seen in Table 2. The probability of infection increases proportionately as
neutropenia worsens and prolongs. Initially, prophylactic antibiotics are administered in attempt
to protect a neutropenic patient from the patient’s own normal flora. The spectrum of activity in
a given antibiotic can allow for prediction of the succeeding infection.

Currently,

fluoroquinolones with antipseudomonal activity are most commonly used, as they are broad
spectrum antibiotics and are useful against endogenous flora found on the skin and in the
gastrointestinal tract. These are the predominant sources of infection throughout neutropenia.
Several days post antimicrobial therapy, the reduction in Gram-negative organisms and ongoing
neutropenia will outfit for pro-Gram-positive selective pressures and allow for bacteremia by
endogenous organisms like Streptococcus viridans, multiple species of Staphylcocci, and
Corynebacteria. These Gram-positive organisms are found in the normal oral flora and on the
skin.

When neutropenia persists into a second week, infections are primarily yeasts like

Candida.

Antibiotics against both Gram-positive and Gram-negative organisms promote

translocation of overgrown yeast species from the GI tract thus increasing the risk for
candidemia (80-82).
The third week of neutropenia consists of higher rates of infections originating in the GI tract,
skin, respiratory tract, and nosocomial infections. Molds like Aspergillus and Fusarium inhaled
before neutropenia set in can result in infection at this time. Although hospitals cannot combat
molds inhaled before hospital admission, air filtrations systems are used to help reduce the risk
of acquisition of these infections from hospital environments. In addition to molds, reactivation
of viruses like Herpes simplex, Varicella zoster, Cytomegalovirus, and Adenovirus and BK virus
are also common during this phase of neutropenia. 70-80% of patients with seropositive Herpes
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simplex will develop an infection which may extend into the esophagus leaving the patients
vulnerable to other infections through damaged mucosal membranes (62). Furthermore, multidrug resistant (MDR) Gram-negative organisms colonizing the GI tract are of concern, as they
are the only microorganisms left after treatment with multiple broad spectrum antibiotics and
they result in serious infections with increased mortality rates.

Recently, drug resistant

pathogens accounted for 34% of bacteremia in cancer patients (83).
Table 2 Trends of Infection Through Duration of Neutropenia in Cancer
Patients
Week of neutropenia
Antibiotic Use
Resulting Infection
Week one

Gram-negative action
antimicrobial

Gram-positive bacteria (i.e.
Staphylcocci, Streptococci,
Corynebacteria)

Week two

addition of Grampositive action
antimicrobial

Yeast (i.e. Candida)

Week three

addition of antifungal

Mold (i.e. Aspergillus,
Fusarium)

Lastly, poly-microbial infections must be considered in an immune depleted patient population.
Unfortunately, a lack in reporting of these infections has kept them under the radar. Recent data
shows that up to 15% of bacteremia in neutropenic patients are poly-microbial. Poly-microbial
infections are even more frequent in sites of pneumonia, enterocolitis and peri-rectal infections
(77, 84, 85).
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Bacterial Infections
Due to constant fluctuation regarding the frequency of Gram-positive and Gram-negative
infections in cancer patients, it is safe to deduce that infectious disease patterns vary with respect
to geographical location and facility (76, 86). However, a few trends have been perceived in the
past decade. Upon initial use of cytotoxic chemotherapy, Gram-negative bacteria, presumably
endogenously acquired from the GI tract, were the most common infections (73, 87).
Subsequently, Gram-positive organisms became responsible for the majority of infections in
neutropenic cancer patients due to Gram-negative directed prophylaxis, central venous catheters,
and frequent oral mucositis (76, 88). Recently, non-fermenting Gram-negative bacilli have
surfaced in cancer patients, including Acinetobacter and Stenotrophomonas, along with the
advancement of MDR organisms (88-93). Finally, the gradual cessation of fluoroquinolone
prophylaxis in some institutions in hopes of prevention of further drug resistance may play a role
in the current shift towards dominance of Gram-negative infections (86).
Gram-positive Organisms
In neutropenic patients, the most frequently isolated Gram-positive is coagulase negative
Staphylococcus (CoNS).

These organisms are considered less virulent than most and are

commonly found in normal flora. The infections caused by CoNS are usually central-lineassociated-bloodstream infections (CLABSI). Staphylococcus epidermidis, S. hominis, and S.
haemolyticus and S. lugdunensis are the most common CoNS isolated from cancer patients (94).
CoNS are also associated with infections in Ommaya reservoirs when accessed numerous times
(95-97). Excluding S. lugdunensis, these infections are ordinarily treated with antimicrobials and
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removal of catheter is sometimes warranted (98). S. lugdunensis is more virulent than the former
and requires treatment similar to S. aureus owing to its increased pathogenicity (99).
S. aureus is a much more serious infection. This is the second most common Gram-positive
species isolated from neutropenic patients. On average, 25% of the population is colonized with
S. aureus in the anterior nares (100).

Immunosuppressed patients have higher rates of

colonization and infections with significantly high morbidity and mortality. Additionally, some
cancers, like Hairy Cell Leukemia, prevent proper functioning of the neutrophils against S.
aureus (101). If the infection is due to CLABSI, antimicrobials are administered and catheter
removal is typically required.

Furthermore, evaluations for endocarditis and abscesses are

essential as S. aureus can swiftly wreak havoc on the heart and epidermis (98).
Furthermore, methicillin resistant S. aureus (MRSA) make empirical treatment of Staphylococci
infections even more challenging. A study in Korea revealed mortality rates of methicillinsusceptible S. aureus (28.8%) compared to MRSA (38.1%) mortality rates with a difference of
almost 10% (102). MRSA colonization is increasing which in turn results in higher rates of
infection by MRSA (100).

MRSA infections have been seen in as much as 55% of

Staphylococci infections in cancer patients regardless of neutropenia and treatment failure rates
of MRSA in cancer patients can be greater than 50% (103, 104). MRSA accounts for almost a
quarter of MDR infections in cancer patients (83). This influx of MRSA infections exacerbates
the use of vancomycin for treatment which, in turn, leads to vancomycin resistance (104).
Infections with Enterococci in cancer patients usually arise after prolonged antimicrobial therapy
with broad- spectrum antibiotics. This alteration in the lower GI tract allows for substantial
increase of Enterococci which can then cause bacteremia by translocation through the GI tract or
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ascending urinary tract infections (105). Unfortunately, increased use of vancomycin due to
MRSA infections may play a part in the most recent 15-20% of Enterococci presenting resistance
to the drug (106). Patients who have received chemotherapy are at a high risk for development
of VRE infections (107). Kamboj published a study in 2010 where 247 patients underwent
hematopoietic stem cell transplants (HSCT). VRE was the leading cause of bacteremia 30 days
post-transplant, accounting for 53.5% of bacteremia infection with a 9% mortality rate (108).
Like MRSA, colonization with VRE can increase likelihood of bacteremia post chemotherapy
(108-110). There is a strong correlation between VRE carriage and development of VRE
infections, specifically infections of bacteremia (110, 111).
Viridans group Streptococci (VGS) is another source of bacteremia in chemotherapy patients.
The most commonly found VGS species found in these infections are S. mitis, S. sanguis and S.
salivarius. Although VGS are normal in oral flora, mucositis of the mouth may allow for
transition into the blood and successive endogenously acquired bacteremia. Therefore, patients
on chemotherapy known to cause excessive oral mucositis, like cytosine arabinoside, are at an
increased risk for VGS infection (112, 113). Fluoroquinolone prophylaxis may also play a part
in encouraging the growth of VGS by destruction of competing organisms. VGS bacteremia can
cause rapid sepsis, presenting as hypotension and acute respiratory distress syndrome (ARDS)
with a 12% mortality rate (113, 114). VGS are also responsible for streptococcal toxic shock
syndrome with a mortality rate between 40-50% regardless of antimicrobial therapy (112-114).
Furthermore, recent documentation of drug-resistance is being seen in multiple facilities. MD
Anderson Cancer Center reports Vancomycin tolerant VGS (115) and Penicillin-resistant VGS
as high as 27% among cancer patients (116). Both Sweden and Spain show similar VGS
penicillin resistance of 20-30% (117, 118).
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Other, less predominant, Gram-positive organisms known to cause infections in cancer patients,
specifically neutropenic patients, include Bacillus spp, Corynebacterium spp, Micrococcus spp.
These tend to cause CLASBSI infections but more serious infections have also been
documented. Bacillus cereus has been isolated in cases of fulminant sepsis and has caused
massive intracellular hemolysis due to production of multiple hemolysins (119, 120).
Furthermore, Corynebacterium jeikeiun has also been reported in cases of sepsis in patients with
ALL. Regrettably, C. jeikeium tends to be resistant to multiple antibiotics and, similarly to C.
diphtheriae in healthy people, C. jeikeium can cause skin and pulmonary lesions in neutropenic
patients (121, 122).
Listeria monocytogenes may also cause infection during immunosuppression by violation of the
central nervous system (CNS).

L. monocytogenes has a high mortality rate in

immunocompromised patients due to invasion in the CNS resulting in meningitis, brain
abscesses, and bacteremia (123, 124).
Gram-negative Organisms
The most common Gram-negative pathogens are endogenously acquired through the GI tract.
These pathogens include Pseudomonas aeruginosa, Escherchia coli and Klebsiella which cause
between 45-60% of Gram-negative infections (77, 88, 118, 125). Each of these organisms may
cause sepsis by endotoxin release in the bloodstream resulting in hypotension, renal failure, and
shock.

Due to their severity, Gram-negative organisms are usually associated with high

morbidity and mortality.

Furthermore, the use of antimicrobial prophylaxis in neutropenic

patients in order to prevent these infections has resulted in the emergence of significant
resistance to quinolones and aminoglycosides among E. coli and other Gram-negative species
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(126, 127). Carbapenems and fluoroquinolones have been identified as risk factors for drug
resistance when used over prolonged periods of time (128).
Despite prophylactic treatment for Gram-negative organisms, Pseudomonas aeruginosa is the
most repeatedly isolated non-fermenting Gram-negative organism due to its remarkable ability to
evade and persist in the GI tract, translocate into the blood, and development of antibiotic
resistance by various mechanisms (129-131).

Hematological disease is associated with an

increased risk for P. aeruginosa bacteremia. A recent study of patients with hematological
malignancies over a 70 month period, who were prophylactically treated with levofloxacin when
neutropenia was expected for greater than 7 days, confirmed 441 bloodstream infections of
which, 15% were identified as P. aeruginosa and 57.3% were Gram-negative. Additionally, one
third of the P. aeruginosa were MDR. The thirty day mortality rates for all bloodstream
infections, P. aeruginosa, and MDR-P.aeruginosa were 11.3%, 27.3% and 36.4% respectively
(132).

In the past decade an increase in fluoroquinolone-resistance has been seen in

P.aeruginosa. Pakistan reports an increases from 13.3%in 2000 to 29.4% in 2006.
Furthermore, P.aeruginosa is the most frequently isolated Gram-negative organism isolated from
poly-microbial infections (84).

Poly-microbial infections that include P.aeruginosa have

mortality rates greater than 50% (133).

Poly-microbial infections are less responsive to

antimicrobial treatments due to their complex nature. They tend to comprise more complicated
infections like pneumonia, enterocolitis, and tissue necrosis where deep tissues are involved.
Recently rates of poly-microbial bacteremia have been documented in 15% cases involving
cancer patients(77).
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Escherichia coli are the most prevalent Gram-negative pathogen, with an impressive ability to
infect multiple mucosal surfaces and more, it is of no surprise that E. coli is a constant threat to
all patients. This broad range of infections can include, UTIs, pneumonia, colitis, bacteremia,
and so on. Lung cancer patients are at risk for pneumonia due to E.coli, these infections have
been reported as high as 37.5% (134). However, this great degree of variability in E. coli can be
even more dangerous in neutropenic patients. Oddity infections, like pyomyositis, have been
documented in neutropenic cancer patients (135). Furthermore, E. coli seems to infect these
patients regardless of targeted antibiotic prophylaxis. Occurrences of bacteremia by E. coli have
been as high as 37% in some patient populations (106).
E. coli is also the frontrunner in fluoroquinolone resistance, which makes this GNB even more
dangerous (136). Variations can be observed based on geographical location and facility but
resistance continues to escalate. Kjellander et. al, study indicated no change in Gram-positive
and Gram-negative bacteremia ratios of 53.1% and 46.9% respectively even though prophylaxis
was halted in an attempt to combat the accumulation of multidrug resistant organisms. E. coli
accounted for 17.8% of these blood isolates.

Furthermore, there was an increase in

fluoroquinolone resistance, 2% in 2001 and 16% in 2008, despite the absence of fluoroquinolone
prophylaxis at this particular facility in Sweden.

Additionally, 36% of patients with

fluoroquinolone-resistant E. coli died within 30 days (118).

A study of hematologic

malignancies in Italy treated half of its patients with fluoroquinolone prophylaxis and
fluoroquinolone-resistant isolates were found in 81% of patients compared to 37% in the nontreated patients (137).

The United States, where quinolones are widely used, also shows

increases in fluoroquinolone-resistant E.coli (127).
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On the other hand, striking decreases of fluoroquinolone-resistant E. coli were seen in the
cessation of quinolone prophylaxis in Spain, 71% in 1996 to 37% in 2010(117).
Variably, Chong et al, reported no quinolone-resistant E. coli during a 2 year time frame of
quinolone prophylaxis at a facility in Japan (138).

As expected, the percentages of Gram-

negative infections at facilities that forgo prophylaxis are increased in comparison to
antimicrobial prophylaxis treated patients (92, 138); however, E. coli infections specifically do
not continually show significant change (117, 138).
Moreover, Extended-spectrum β-lactamase-producing (ESBL) E. coli is also an emerging
worldwide pathogen and has proven to be particularly unforgiving in cancer patients (139, 140).
In a single center investigation, cancer patients receiving antimicrobials had higher rates of
ESBL E. coli bacteremia than patients who were not receiving antimicrobials. Furthermore,
12.6% of all E. coli bacteremia cases were caused by ESBL E. coli. The patients with ESBL E.
coli also had higher mortality rates than non-ESBL inflicted patients. Analysis of ESBL genes
from this study did not support a clonal spread as CTX-M, SHV and TEM were 74%, 19% and
7% predominance respectively (141). A similar study at a single facility in Italy showed higher
ESBL E. coli prevalence and once again polyclonal distribution was exhibited by TEM, 36%,
CTX-M, 33% and SHV, 31% (137).

Although some monoclonal nosocomial dispersion has

been suggested based on TEM, CTX-M and SHV data, there are other risk factors for acquisition
of ESBL E. coli bacteremia (138). Previous exposure to fluoroquinolones and carriage of ESBL
E. coli have been identified as potential risk factors for bacteremia in cancer patients (110).
Klebsiella spp. is consistently the third most prevalent Gram-negative organism isolated from
bacteremia in cancer patients and frequently accounts for about 10% of infections in neutropenic
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patients (106, 118, 138). Recent attempts to forgo antimicrobial prophylaxis have allowed
Klebsiella spp., which colonize the GI tract, to more readily invade and cause infections in
cancer patients (138).

Unfortunately, Klebsiella is also an ESBL-producing bacterium.

It

appears as though ESBL Klebsiella may be acquired in the community as studies show even
after a 3-year period of stopped antimicrobial prophylaxis, 14.3% K. pneumoniae isolates from
infections were ESBL-producers. This is indicative of communal acquisition of isolates which
have now colonized the GI tract of patients. These ESBL strains were, like ESBL E. coli,
predominately CTX-M which seems to be a global commonality (138) .
Although non-fermenting Gram-negative bacilli (NFGNB) are less frequently encountered they
are making notable increases in the proportion of Gram-negative infections among cancer
patients specifically with regard to Pseudomonas aeruginosa, Acinetobacter spp., and
Stenotrophomonas maltophilia (142). P. aeruginosa makes up a large part of the 40% of Gramnegative infections caused by NLFGNB. It is the most frequently isolated NFGNB as it accounts
for approximately 15-20% of Gram-negative infections in cancer patients. P. aeruginosa is not a
novel problem and it has been seen in severe infections for decades (132, 143). Conversely, S.
maltophilia, have not been seen as often in the past and are currently making headway in
hematological cancer patients. This NLFGNB is frequently multi-drug resistant and is not
susceptible to fluoroquinolones that are commonly used in cancer patients making it incredibly
dangerous under these circumstances (144, 145).
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CHAPTER TWO:
MOLECULAR EPIDEMIOLOGY OF ESCHERICHIA COLI CAUSING
EXTRAINTESTINAL INFECTIONS IN PATIENTS WITH CANCER

Introduction
Phylogeny of Escherichia coli
The species Escherichia coli is a prominent member of the Enterbacteriacae Family. With an
assortment of variable strains, E. coli plays a major role in both health and infection of the
human body. Commensal strains of E. coli are best known for their role as major facultative
anaerobes of intestinal microflora. They colonize hours after birth and thrive with upwards of
500 other bacteria in the mucosal lining of the colon. Here they persist for the remainder of life
and aid in protection, digestion and absorption in the gut (1). Survival in this competitive
environment of various organisms and host interactions requires significant ability to adapt. The
ability of E. coli to acclimate under selective pressures is what has led to the great divide in
commensal and pathogenic isolates.

E. coli uses a multitude of metabolic and regulatory

mechanisms to adjust to countless environmental stressors (2-6).
The main pathogenic types of E. coli include intestinal pathogenic E. coli (IPEC) and
extraintestinal pathogenic E. coli (ExPEC). These can be further delineated based on pathogenic
traits as enteroaggregative E. coli (EAEC), enterohemorrhagic E. coli (EHEC), enterotoxigenic
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E. coli (ETEC), enteroinvasive E. coli (EIEC), enteropathogenic E. coli (EPEC), diffusely
adherent E. coli (DHEC) and adherent-invasive E. coli (AIEC), which are generally categorized
under IPEC. While ExPEC have further defined pathotypes of menengitis-associated E. coli
(MNEC), septicemia-associated E. coli (SEPEC), urinary tract infection or uropathogenic strains
(UPEC) and avian pathogenic E. coli (APEC)(2, 3, 7).
Deletion and acquisition of DNA is a critical part of prokaryotic evolution and the plasticity with
which E. coli is able to accomplish this is largely what makes it such a successful
microorganism. Thus, the various pathogenic strains of E. coli do not have a single evolutionary
origin within E. coli but have risen numerous times.

Strains can acquire the appropriate

virulence factors to give rise to a pathogenic form (8). E. coli was one of the first organisms
used to display the importance of these exchanges as it maintains the ability to laterally acquire
and transfer genes in order to promote survival in the host. Multi-locus enzyme electrophoresis
(MLEE) work by Selander and Whittam demonstrates that although the single locus-diversity
estimates suggest neutral gene theory, combinations of alleles into electrophoretic types indicate
genetic differentiation into distinct groupings by particular genetic combinations via selective
differences (9). Furthermore, acquired virulence factors, which allow the cell to adhere to tissue
surfaces, evade the immune system and disseminate through the body are also associated with
pathogenic E. coli (10-13). Therefore, each of the classifications of E. coli pathotypes is based
on phylogenic background, virulence factors and the obvious clinical manifestation of disease.
An E. coli (ECOR) reference collection established by Whittam, Ochman and Selander was
originally used to phylogroup by MLEE (9). This classification is largely true today and is
currently used as a reference tool to designate isolates into one of the four major lineages, A, B1,
B2, D. Commensal strains belong mainly to phylogenetic groups A and B1, are devoid of most
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virulence factors, they are sister taxa. Some strains of A, B1 but more so D, are pathogenic and
often maintain an increased number of virulence factors. However, commensal strains can be
isolated

from

pathogenic

conditions

suggestive

of

host-dependent

factors

like

immunosuppression from underlying disease. Pathogenic E. coli found in infections of healthy
individuals is most frequently associated with phylogenetic groups B2 and D. B2 is a divergent
lineage associated with increased virulence and high mortality upon in vivo challenge (14).
Furthermore, increases in MLST data sets and further characterization of a greater number of
strains have evolved to document ancillary phylogroups E,C, and F. Phylogroup E, which was
the first of these recognized accessory groups, is now well characterized and contains the famous
O157:H7 pathogenic EHEC strain. Phylogroups C and F are closely related to B2 and B1
phylogroups respectively (1).

There is an apparent interdependency of pathogenicity and

metabolic activities displaying by correlation of phylogeny and pathogenicity (15).
The Problem of ExPEC
E. coli has the ability to infect and disseminate through every mucosal surface in the human body
(16). Due to a unique capability to adapt to a multitude of environments, ExPEC is the single
most prevalent pathogen for all urinary tract infection syndromes, resulting in upward of 1.5
billion dollars in healthcare costs a year. Each year E. coli is responsible for over one hundred
thousand cases of sepsis, approximately forty-thousand sepsis-related deaths and tens of
thousands of cases of pneumonia (17). Furthermore, treatment of E. coli infections with standard
antibiotics is increasingly ineffective due to drug resistance of the adaptive organism. This drug
resistance in E. coli is associated with higher mortality rates in patients (10).

38

Recent reports of clinical ExPEC investigations demonstrate variability of E. coli to be
extraintestinally infective even though the phylogroup it belongs to may not characteristically be
of a pathogenic origin (18). Extraintestinal E. coli strains frequently originate from the intestines
and are physiologically fit for invasion outside of the gut. This invasion results in endogenously
acquired bacteremia. The variability of these phylogenetic relationships and virulence factors
throughout ExPEC strains can allow for novel sequence types and dissimilar virulence patterns
resulting from selective pressures in the environment.
ExPEC in Cancer Patients
Depleted immunity and extended hospital visits make cancer patients inordinate hosts for the
acquisition of novel pathogenic infections.

Chemotherapy, solid tumor cancers and prior

antibiotic usage have been identified as risk factors for extraintestinal E. coli infections (19-22).
The alterations of environment in cancer patients, such as chemotherapy treatments, radiation,
drugs and prophylactic antibiotic treatment, could very likely allude to a rapid evolutionary
pattern in E. coli genotypes, resistance patterns, and virulence factors in ExPEC infections.
Ironically, the same interventions used to treat cancer are also variables which increase risks of
bacterial infections. These infections interfere with chemotherapy treatment in cancer patients
and are greatly associated with increases in morbidity and mortality. Although some risk factors
are known, there is a critical lack of knowledge in the types of E. coli infecting cancer patients.
For example, in 2010 M.D. Anderson Cancer Center linked E. coli with deadly pyomyositis
infections. In a normal patient population, ninety percent of pyomyositis infections are caused
by Gram positive organisms. Furthermore, the oddity Gram negative pyomyositis infections in
this population are largely harmless.

Conversely, in cancer patients with hematologic
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malignancies, a 33% mortality rate was documented and molecular analysis of the 6 available
isolates proved 5 to be from the same lineage, ST131 (11). This lethal sequence type is
implicated in extended-spectrum beta-lactamase production which results in increased antibiotic
resistance. As this type of infection is uncommon in a healthy patient population and empirical
treatment is the most influential variable in mortality rates of cancer patients, characterization of
extraintestinal E. coli isolated from cancer patients by genotypes is critical to understanding the
ExPEC infections debilitating these patients (22).
More recently, a significant shift from Gram positive to Gram negative bacterial infections has
been documented in patients with cancer. In 2008 a large-scale association between cancer
patients and multi-drug resistant E. coli was reported during a 16 month screen. 823 patients
from a cancer center in Italy demonstrated a significant change in the types of bacteria infecting
cancer patients with hematological malignancies. The majority of isolates were Gram negative
and a quarter of all specimens were E. coli.

Hospital protocol prophylaxis employed

fluoroquinolone antibiotics if neutropenia was present for greater than seven days. 87% of the
ExPEC from these patients was found to be resistant to fluoroquinolone and 97% of patients on
prophylaxis presented with fluoroquinolone resistant ExPEC. Moreover, of patients who did not
receive prophylaxis, only 44% were infected with fluoroquinolone resistant extraintestinal E.
coli.
In 2009, another correlation was found between ExPEC infections and patients with cancer at
MD Anderson Cancer Center. Cancer patients were inundated with multi-drug resistant E. coli
in cases of bacteremia. This resistance was thought to be selected for by prophylactic treatment
with fluoroquinolones which then allowed for explicit fluoroquinolone resistance types of E. coli
to persist in these patients.

A similar consequence of bacterial infections in allogeneic
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hematopoietic stem cell transplant recipients at Mayo Clinic was documented from 2003-2008
when prophylaxis entailed levofloxacin and either penicillin or doxycycline.

While Gram

negative organisms did not account for a single infection in 2003, Gram-negatives progressively
escalated to 46% in 2008. Of those, multidrug resistance was seen strictly in the classes of drug
for which patients were prophylactically treated (19).
Insufficient treatment of Gram negative infections has resulted in a change in the epidemiology
and antibiotic resistance of previously easily treated infections (21). In patients with cancer,
initial accurate treatment is crucial to the outcome of infection. A single study reported a
mortality risk ratio from multi-drug resistant E. coli greater than 6 times that of non-multi-drug
resistant isolates from the same facility. Increases in drug resistance play a significant role in the
inability to cure infections, in turn, increasing morbidity and mortality rates in cancer patients
(22).
Unfortunately, we have yet to expose all of the risk factors of cancer and cancer therapy due to a
lack of comprehensive knowledge regarding the ExPEC infections and how they correlate to
cancer and cancer treatment. Steps must be taken to identify high risk cancer patients and
discernible flags from these types of E. coli infections must be sought out for improved
prevention and management of ExPEC infections in cancer patients.

Evidence shows that

adequate empirical antibiotic treatment plays a critical role in the outcome of infection. A study
to assess antibiotic resistance, adequacy of initial antibiotic therapy and patient mortality of
specimens from 1997-2005 at Sierrallana Hospital, in Spain inferred multidrug resistance played
a significant role in incorrect empirical antibiotic treatment and patients with MDR E. coli had
significantly higher mortality than non-MDR E. coli hosts (22).
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A retrospective, double matched, case-control study in 2008 resolved that statistically significant
risk factors for bacteremia with multi-drug resistant E. coli in cancer patients are chemotherapy,
surgery and radiation within 30 days prior to infection.

Cancer patients undergoing these

procedures commonly receive prophylactic antibiotic treatment. The study also suggests that
these two factors may result in multi-drug resistant E. coli in the bloodstream because of mucosal
upset of native microflora (19). A sixteen year study at Rabin Medical Center in Israel proved
that resistance of the Gram-negative bacteria to broad-spectrum beta-lactams used to treat
febrile neutropenia, a common ailment in cancer patients, increased with length of hospital stay
prior to onset of bacteremia increasing from 8% acquired before hospitalization to 48% when
acquired  14  days  after  admission.    Similar  resistance  trends  were  seen  in  the  children’s  hospital  
with length of hospital stay. More individualized approaches are necessary based on antibiotic
exposure and other risk factors like length of hospital stay (20).
In cancer patients, the problem of ExPEC is exaggerated.

E. coli infections interfere with

chemotherapy treatment, increase patient mortality rates and healthcare costs (23). The
circumstances surrounding these patients make them inordinate hosts for development and
transmission of resistant organisms, yet there is a gap in knowledge about the specific types of E.
coli affecting patients with cancer.
Aims
Aim 1: Define the genotypes and clonal groups attributable to ExPEC infections in patients with
cancer from H. Lee Moffitt Cancer Center (MCC).
Multilocus sequence typing (MLST) will be used to assign genotypes to clinical and
control isolates of E. coli. The genetic relatedness of MCC and to reference control
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collections will be determined using molecular phylogenetic analyses. MLST will be
used to model the evolutionary history, population structure and patterns of dissemination
of E. coli causing extraintestinal disease at MCC.
Aim 2: Determine the antibiotic resistance and virulence attributes of ExPEC infections in cancer
patients.
Antibiotic susceptibility testing will be performed using disk diffusion. Multiplex PCR
will be used to define the profile of virulence factors associated with extraintestinal
disease in MCC E. coli isolates compared to control strains.
Results
Patient Population

Table 3. Patient Gender and Site of Infection
Site of Infection Female Male Unknown* Total Infections
Wound
6
8
1
15
Blood
4
8
3
15
Urine
44
22
66
Abdominal Fluid
5
6
11
Other
3
1
4
Sputum
0
3
3
Total
62
48
4
114
*Unknown gender information resulted from damage to isolate label.

%
Total
13%
13%
58%
10%
4%
3%
100%

114 cases of ExPEC infections were collected from MCC between 2009 and 2013. Most patients
were female (56% of cases). The average patient age was 61 with the youngest patient being 22
and the oldest 90. There was no significant difference in average age of infection between
genders. Table 1 shows population gender and sites of infection. The most common site of
infection was the urinary tract followed by the blood and wounds.
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MLST Analysis
DNA sequencing via MLST allowed for direct assignment of multiple housekeeping alleles. The
5’ ends of seven housekeeping genes (aspC, clpX, fadD, icdA, lysP, mdh and uidA) were
sequenced and consensus sequences were assembled for genes in each of the MCC isolates.
Sequence comparisons among 105 isolates revealed 24 distinct combinations, not including 17
non-typeable isolates. Non-typeable isolates contain MLST profiles not found in the EcMLST
database.

Singlets
17%

ST34
39%
NT
16%

ExPEC
16% ST171
4%

ST618
ST260 3%
5%

Figure 1 Distribution of Sequence Types
(ST) ExPEC include ST27,ST31 and ST29.
Singlets refer to sequence types represented
by a single isolate; non-typeable (NT).

Among the 24 distinct sequence types (ST) there were 17 singletons and 7 STs isolated more
than once. Distribution of common STs is seen in Figure 1. Classic extraintestinal E. coli
(ExPEC) (ST27,ST31 and ST29) make up only 16% of total isolates. ST27 and ST31 are
uropathogenic genotypes, while ST29 is a neonatal meningitis genotype.

ST171 is

characteristically a Shiga-toxin producing (STEC) genotype, whereas ST34, ST260 and ST618
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are genotypes associated with enteroaggregative E. coli (EAEC).
The most commonly isolated STs (three or more times) are seen in Figure 2. These isolates
include ST27, ST29, ST31, ST34, ST171, ST260 and ST618. They make up 67.6% of total
isolates and are found in each of the sites of infection. ST34, was the overwhelmingly the most
frequently isolated ST and occurred in every site of infection. Half of ST171 and related NT
isolates were found in the blood. The urinary tract was the site of infection for more than half
(58%) of the most common STs seen here and a quarter of the remaining common STs are from
wound (14%) and blood (10%) infections.

80
70

Number of Isolates

60
50
40
30
20
10
0

ST 27 ST 29 ST 31
Wound

Blood

Urine

ST34 ST 171 ST 260 ST 618 Total

Abdominal Fluid

Other

Sputum

Unknown

Figure 2 Most Commonly Isolated STs with Associated Infection

Sites
Phylogenetic Analysis
Commensal and pathogenic E. coli strains can be divided into four major phylogroups referred to
as the ECOR A, B1, B2 and D groups (24). Typically commensal strains belong to groups A and
B1, whereas E. coli associated with ExPEC are found in B2 and to a lesser extent D. To
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determine the distribution of ECOR phylogroups among ExPEC infecting cancer patients we
compared strains with known ECOR reference strains as seen in Figure 3.

A MUSCLE

alignment was used to construct a Neighbor-joining tree through MEGA5.05. MCC isolates
cluster into six clonal clusters (Clonal Clusters I-VI). Bootstrap values, indicated at nodes, were
used to define clonal clusters when values were greater than 70%. Moffitt isolates are indicated
by MCC numbers, clinical reference strains are denoted by TW numbers, and phylogroup
reference strains are indicated by ECOR numbers.

These clusters show a lack of classic

extraintestinal pathogenic E. coli. Only 22% of these isolates cluster with the phylogroup B2,
seen in Clonal Clusters II-IV, strains typically known to cause extraintestinal infections. Instead,
the majority cluster north of B2 isolates.

This outliner of B2 phylogroup contains ST34

representing 39% (42 isolates) of the total isolates from Moffitt patients.

This particular

sequence type does not cluster with any of the recognized A, B1, B2, or D phylogroups.
SNP ST131 PCR
Based on the location of ST131 control strains in the cluster analyses, PCR was used to
determine if ST34 by EcMLST MLST method is ST131 by Achtman MLST method as
conducted  in  “ST131   E. coli SNPs   PCR   Protocol:  Johnson   Lab   protocol/Brian  Johnston,  2008”  
and optimized for Riordan Lab. SNP specific PCR products in mdh and gyr genes are associated
exclusively with ST131 strains as seen on the Achtman MLST website: http://mlst.ucc.ie/mlst/.
Of the ST34s analyzed, as seen in Figure 4, 90% were positive for SNP specific PCR products in
mdh

and

gyr

as

well

as

the

uidA

control.
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RAPD Analysis
RAPD-PCR was employed to assess the clonality of the most common ST, ST34. Visual
comparisons of randomly amplified banding, seen in Figure 5, does not suggest an exact clonal
match but instead appears to be multiple fingerprints suggestive of variable strains of ST34.
Additionally, due to the similarity of determinative SNPs with ST131, ST131 control strains,

Figure 4: ST131 SNP 1.5% agarose gels containing Johnson Lab ST131 positive control, empty DNA
template and and clinical ST34 isolates. PCR products include uidA (508 bases pairs), mdh36 (275 base
pairs), and gyrB47 (130 base pairs).

were used and again suggest possible disparities in ST by various MLST methods as they also
cluster closely with ST34 in RAPD analysis.
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Antimicrobial Susceptibility
As seen in Figure 6, Ciprofloxacin, a commonly used fluoroquinolone, proved to be the least
successful antimicrobial tested, as 53% of Moffitt isolates are not treatable with the drug.
Ciprofloxacin resistance is frequently seen in the healthcare setting (25).

Additionally,

trimethoprim-sulfamethoxazole was unsuccessful in 39% of ExPEC isolates at Moffitt.
Imipenem and cefipime (both cephalosporins) showed the greatest counteractive response
against MCC isolates. Of 113 specimens tested for drug resistance, 23% display potential for
multidrug resistance, which is defined by resistance to three or more drugs each with a dissimilar
mechanism of action. Furthermore, 5% of the isolates show potential for Extended-spectrum
beta-lactamase production via resistance to extended-spectrum cephalosporins, ceftazidime and
ceftriaxone. One isolate was rejected for antibiotic profiling due to inability to confirm patient
data attached to it.
Virulence Profiling
The distribution of virulence factors was evaluated using multiplex PCR. Virulence factors
assessed included adhesins, specifically, P fimbriae (papA), S and F1C fimbriae(sfa, focG), and
type 1 fimbriae (fimH), additionally, capsule synthesis (kpsMT), iron scavenging systems (iutA),
toxins to include hemolysin and shigatoxin (hlyA, stx2A), and serum survival factor (traT).
Previous work shows specialization of these virulence factors implicated in ExPEC E.coli and
lacking in commensal E.coli isolates (14).
Well-characterized E. coli strains were used for both positive and negative controls. The first 8
of these are commonly seen in extraintestinal E. coli while the last two factors are more
frequently expressed in enterotoxigenic E. coli and other enteric E. coli strains. The uncommon
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B2 isolates in this patient population had an average of 3 VFs per profile and the non-B2, ST34s,
also had an average of 3 virulence factors per profile. More specifically, the ST34 profiles
consisted of 97.5% fimH, 85.4% iutA, and 90.2% traT.
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Figure 6 Antimicrobial Resistance of MCC Isolates
Piperacillin-tazobactam(PT);
Imipenem(IMP); Ceftiaxone(CEF); Ceftazidime(CAZ); Cefepime(CFPM); Gentamycin(GEN);
Tobramycin(TBM); Ciprofloxacin(CIP); Trimethoprim-sulfamethoxazole(TMP-sulfa)
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Figure 7 Comparison of MCC B2 and non-B2 Virulence
Adhesions :fimH, focG, papA, sfa; Siderophore:iutA; Protectin:
traT; Toxin: hlyA; capsule synthesis: kpsMT

Although the B2 phylogroup had increased adhesions, toxins and capsule synthesis, the
pathogenic ST34 group had greater siderophores and protectins, see Figure 7. Furthermore, in
comparison, the virulence potential for clonal cluster 1, containing the ST34, was roughly three.
Classic pathogenic B2-clusters exhibit about the same virulence potential as these un-common
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outliers of B2, as seen in Table 2.
EAEC-PCR
Type-specific PCR targeting the pAA plasmid was performed on all ST34 isolates using
pCVD432 primers with EAEC042 and JJ055 controls. No amplification resulted for any of the
ST34 strains from the study.

Discussion
Previous studies by Selander and Whittam suggest that differentiation in electrophoretic types
are associated with genetic differences into distinct groups, of which, some show a propensity to
cause disease in the gastrointestinal tract due to specific virulence factors and the ability to create
a definite fitness niche.

This determination permitted the site specific naming of many

pathotypes, like IPEC and ExPEC. However, our investigation of sequence types associated
with ExPEC infections in cancer patients has brought to light some possible variation in roles of
previously  characterized  “enteric  pathogenic  E.  coli”.
Genotypic analysis identified a novel predominating sequence type unassociated with
conventional ExPEC infections, ST34.

ST34 is an infrequently found ST related to

enteroaggregative E. coli (EAEC). EAEC is most commonly associated with diarrheagenic
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disease of acute and chronic nature and is independent of the level of economic development (26,
27). The EAEC pathotype is heterogenic in nature and is defined  by  a  “stacked  brick”  adherence  
pattern to epithelial cells (28). Currently, the most accepted method for EAEC detection is a
HEp-2 adherence assay. Probing for genetic markers containing virulence genes like the pAA
plasmid is also used to identify EAEC. Unfortunately, not all diarrheagenic strains of E. coli
contain the pAA plasmid therefore EAEC is not exclusive to this mobile element (29, 30).
Based on the pCVD432 probe for the pAA plasmid, our ST34 isolates do not catalog with pAA
positive EAEC isolates (data not shown).

However, their phylogenetic grouping suggests

relatedness to clinically described EAEC diarrheagenic isolates from the Whittam Lab. HEp-2
adherence assays are necessary to further characterize this ST34 group of clinical isolates.
However, based on RAPD-PCR fingerprinting and SNP-ST131 PCR, ST34 isolates are
strikingly similar and may be equivalent to ST131 by other MLST methods.

This is a

forthcoming ExPEC clone described to possess both high virulence potential and antibiotic
resistance in many countries (31). ST131s most frequently belong to phylogroup B2 while our
ST34s cluster appear to fall outside of the B2 phylogroup and is associated with a clinical
enteroaggregative E. coli opposed to ExPEC (32). Yet, EAEC strains most commonly cluster in
phylogroup D, as did our EAEC042 control strain (33).
ST34 isolates seen in MCC patients clearly have the ability to cause infection outside of the
gastrointestinal tract, especially in immunocompromised hosts. Based on our panel of virulence
factors specific to ExPEC E. coli, ST34 isolates have the virulence potential just as significant as
the pathogenic B2 isolates. Furthermore, the prevalence of iutA and traT genes is blatantly
higher in the ST34 cluster when compared to the B2 phylogroup from this study. Previous
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studies have revealed that these two virulence factors are higher in ESBL-producing E. coli
isolates (34).

Although, ESBL production was suspect in many of our isolates, PCR

confirmation is still essential for future studies.
The characterization of the antibiotic profiles may lead to enhanced primary treatment of
extraintestinal E. coli infections in cancer patients. The excessive presence of ciprofloxacin
resistance (53%) may warrant consideration of various other prophylaxis measures in cancer
facilities. Based on the established trends, these variables which allow for pathogenicity of the
organism, may be used as predictive markers for infections and allow for a more efficient
manner of treating patients at Moffitt Cancer Center. Should these types of E. coli exist
unilaterally in cancer patients at multiple facilities, the study of these correlations to cancer
therapy has the potential to impact the entire medical community by altering prevention and
treatment protocol for patients suffering from both cancer and extraintestinal E. coli infections.
Furthermore, clustering indicates the ST171 and closely related non-typeable (NT) isolates,
predominately isolated from blood, are closely related to the clinical STEC strain, TW06296.
This STEC strain is typed as a ST171 and possesses the Shiga toxin gene stx2AB. We have
found no documentation of dissemination into the blood from this STEC. However, MCC
ST171 and closely related NTs may show proclivity to disseminate into the blood via an
unknown fitness niche in cancer patients, as five of the seven were recovered from this source.
These isolates showed little similarity in antibiotic resistance and virulence factor profiles. The
clustering of ST171s with clinical STEC warrants further investigation into the interworking of
this sequence type.
Characterization  of  these   isolates’  virulence   factors may also bring forth patterns of commonly
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perceived virulence genes providing a target for rapid PCR detection in order to direct initial
antimicrobial treatment. For example, ST34 have a high rate of ciprofloxacin resistance and
90% of isolates contain the virulence factor traT. Significant associations have also been made
between specific virulence factors and weakened immunity which further commands the need for
investigation into the parallels of virulence factors and cancer therapy, as this was not considered
previously (14).
Experimental Methods
Clinical Isolates and Cultures
ExPEC isolates were clinically confirmed by Moffitt Cancer Center laboratory personnel.
Isolates were streaked to Tryptic Soy Agar slants and transported to the Riordan Lab on ice and
labeled sequentially in order of collection. Slants were plated to Luria Broth (LB) Agar (1.5%)
and MacConkey Agar plates respectively; then incubated at 37°C for 18 hours.

Upon

confirmation via phenotypic single organism morphology, a negative Gram stain result and
positive lactose fermentation on MacConkey Agar, single colonies were taken from
corresponding LB Agar plates and overnight cultures were made using a 1:10 ratio of media -toflask volume and incubated at 37°C on a rotary shaker (200RPM). Aliquots were prepared with
LB containing %15(v/v final) glycerol and stored at -70°C.
DNA Extraction
DNA extractions were taken from single colony isolates that had been inoculated into 10ml Luria
Broth and incubated, while rocking, at 37°C until exponential growth phase. As advised by
Gentra Puregene DNA Extraction Protocol, 1ml of culture was centrifuged at 15000rcf for 5
seconds and supernatant was discarded. This was repeated for a second ml of culture. 600µl of
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Cell Lysis Solution was added to the bacterial pellet and mixed by pipetting. This tube was them
incubated at 80°C for 8 minutes to lyse the cells. Upon visual clearing of the mixture, 3µl of
RNaseA solution was added to the tube, inverted 25 times, and incubated at 37°C for 45 minutes.
The sample was then immediately transferred to ice for 2 minutes. 200µl of Protein Precipitation
Solution was added to the solution and vortex for 20 seconds.

Finally the samples were

centrifuged for 3 minutes at 15000 rcf to produce a protein pellet at the extremity of the tube.
Supernatant was removed and DNA was precipitated using 600µl 100% isopropanol and
inverted 50 times. Globular DNA was visualized and tube spun 15000rcf for 1 min. 600µl 70%
Ethyl alcohol was added to the pellet and inverted 50 times, then centrifuged 15000rcf for 1 min.
Supernatant was removed by pipetting and tube was inverted to allow drying of ethyl alcohol.
Finally, 50µl of autoclaved distilled deionized water was pipetted into the tube in order to lift
pellet into solution and 2 hours incubation at 65°C successfully triggered DNA into solution.
Multilocus Sequence Typing (MLST) and Phylogenetic Analysis
Sequencing methodology used for MLST was carried out as part of a system described in detail
at http://www.shigatox.net/new/tools/ecmlst.html.
fadD, icdA, lysP, mdh,

In total, 7 housekeeping genes (aspC, clpX,

and uidA.) were analyzed at various positions around the E. coli

chromosome (35). Primers used to amplify these loci were obtained from a publicly available
database at Michigan State University (MSU; www.shigatox.net) and optimized for the Riordan
Lab. Upon electrophoretic confirmation, remaining PCR product was purified using QIAquick
PCR Purification Protocol and sent to MWG Operon.
Once sequenced through MWG Operon by dideoxy sequencing, a pairwise analysis was
constructed of raw data with MEGA5.05 software. Each trimmed sequence was aligned with
K12 reference strain alleles and then compared to sequences in the EcMLST database. Alleles
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are assigned based on DNA sequences. Genotypes are assigned based on allele assignment.
This data was subsequently used to determine the genetic relatedness of Moffitt isolates to one
another by phylogenetic inference and then compared to well-characterized strains. If strains
were absent from the database they were considered new sequence types and added to the
database.

A Neighbor Joining algorithm available through MEGA5.05 was performed on

concatenated MLST DNA sequence data with bootstrap confidence values (1000 replications).
STs which shared >70% bootstrap support were defined as discrete ST clonal complexes.
RAPD PCR
Random amplified polymorphic DNA (RAPD) fingerprints were generated for ST34 isolates, in
duplicate, using the arbitrary primer 1283 to assess the clonality of the ST (36). Reactions were
performed in 25 µl volumes containing 25ng of E. coli genomic DNA and 25pmol of primer
1283. Amplification in a thermal cycler included an initial denaturation of 5 minutes at 95°C
followed by 45 cycles at 95°C, 36°C, and 72°C for 1 minute, 1 minute and 2 minutes
respectively. Amplified products were separated by electrophoresis on a 1.5% agarose gel.
These patterns were visually compared and transferred into BioNumerics® for analysis.
Similarity in banding was compared using the Dice Similarity Coefficient with 1.25%
optimization and 1.25% tolerance. Dendrograms were then constructed according to UPGMA
analysis.
ST131 E.coli SNPs PCR
PCR was used to determine if ST34 E.coli by EcMLST method sequence types as a ST131 by
Achtman MLST. Concentrations and thermocycler settings were optimized for the Riordan Lab
using a Johnson Lab protocol outline and primers in Table 3. ST131 O25B:H4 was use as a
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positive control.

Antibiotic Resistance
Antibiotic resistance profiles were evaluated by standardized disk diffusion according to Clinical
Laboratory Standards Institute.

Nine clinically relevant antibiotics were used to assess

susceptibility/resistance of each isolate.

Extended-spectrum Beta-lactamase production was

confirmed by correlation with patient medical chart data for clinical microbiology laboratory for
evidence of resistance to first and second generation cephalosporin in disk diffusion.
Virulence Profiling
Multiplex PCR
Multiplex PCR evaluated the distribution of virulence factors.

Virulence factors assessed

included adhesion factors (fimH, focG , papA, sfa), capsule synthesis (kpsMT), iron scavenging
systems (iutA), toxins (hlyA, stx2A), and serum survival factor (traT) as described by Johnson et.
al. (11-14). Primers were validated individually using template DNA from well-characterized
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E. coli strains for positive and negative controls. hlyA was assessed in a single-plex reaction for
undergraduate training. Upon confirmation, pooling of primer optimization was assessed by
primer compatibility and product size with relevant DNA template on electrophoretic gel. Final
two pools can be seen in Table 6. Gel electrophoresis was used to confirm the quality of each
multiplex reaction (Figure 8).

Type Specific PCR
EAEC-PCR
Type-specific PCR was performed on ST34s, as they clustered with known EAEC clinical
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isolates in phylogenic analysis. EAEC screening was performed via the specific EcoRI-PstI
fragment on the pAA plasmid. Primers used were pCVD432/start   (5’-CTGGCG AAA GAC
TGT ATC AT-3’)   and   pCVD432/stop   (5’-CAA TGT ATAGAA ATC CGC TGT T-3’)   for   30  
cycles as described by Schmidt et al (37). Positive and negative controls were completed with
each cycle, the Giron Lab EAEC042 strain and the Johnson Lab JJ055 respectively.

7-16-13 (#2)
Pos Neg

Figure
8
Multi-plex
PCR
Pools
Electrophoresis gel for Pool 1 (left) and
Pool 2 (right). JJ055 DNA template was used
as a negative control. CFT073 DNA template
was the positive control for Pool 1 of iutA
(189bp), focG (385bp) and kpsMT (611bp).
The positive control used for Pool 2, papA
(205bp), fimH (248bp), traT (323bp) and sfa
(410bp), was a 50/50 mix of CFT073 and
EAEC042 DNA template.

Stx-PCR
ST171s were tested for stx2A and upon banding, stx2ab for further potential shiga toxin
production using TW06296 and K12 for positive and negative controls respectively. Primers
were   created   using   stx2A530/start   (5’- CAG AGC AGT TCT GCG TTT G- 3’)   and  
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stx2A704/stop  (5’- CGA TAC TCC GGA AGC ACA TT-3’).
Blood Assay
Isolates MCC1- MCC116 were sequentially streaked to 5% Sheep Blood Agar Plates and placed
in ambient air incubators at 37°C for 18 hours. Analysis of colonies was defined as production
of no hemolysis, partial hemolysis or complete hemolysis. A white light was placed under each
plate for clarity. CFT073 and JJ055 were positive and negative controls respectively.
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CHAPTER THREE:
CONCLUDING REMARKS

These phlogenetic striations from normal ExPEC E. coli pathogens warrant further investigation
into the interworking of the E. coli types infecting cancer patients. Next generation whole
genome sequencing and Southern blot hybridization should be employed to further investigate
important clonal groups/sequence types in the patient population at MCC and other cancer
centers to discover mechanisms behind novel virulence, antibiotic resistance and other factors
promoting this fitness niche.
Whole genome sequencing will enable deciphering of specific mutations which may currently be
undocumented due to constant fluctuation in pathogenic E. coli. If upon further confirmation,
this predominating sequence type is ST131, previous whole genome sequencing studies of
clinical E. coli ST131 suggest incredible diversity of three clades within this particular sequence
type due to increased recombination events(1). ST131 has been associated with the spread of
extended-spectrum

beta-lactamase

(ESBL)

clones.

Additionally,

fluoroquinolone,

aminoglycoside, trimethoprim-sulfamethoxazole and carbapenem resistance have all been
documented in ST131 isolates (2, 3) .
Many studies support a dissimilar array of virulence genes within the ST131 group. This
disparity in virulence genes results in unknown virulence potential in each individual case.
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Continuing whole genome sequencing may expose specific sequence trends within the genome
to allow for better detection and assessment of pathogenicity. Previous sequencing provides
insight into the fluoroquinolone resistance found in some ST131 strains showing point mutations
in gyrA and parC genes (4). Whole genome sequencing will help to determine if similar
mutations are responsible for other types of antibiotic resistance and virulence. This data may
also be useful in detection of amino acid changes which impact cell function.
The unpredictable pathogenicity of ST131 strains in the clinical setting presents a critical need to
better understand these types of E. coli for assisting in prevention and treatment of infections.
The success of this pathogen specifically in cancer patients, where the mortality and morbidity
are even greater than the normal population, should merit whole genome sequencing in order to
describe the intricacies of this emerging pathogen.
Furthermore, collection of stool specimens pre-infection and post would be helpful in continued
studies to assess if the cancer patient gut harbors specific disease causing E.coli that may not be
as common or problematic in healthy individuals.

Surveillance and selective digestive

decolonization may be necessary to thwart such drug resistant E.coli in cases of drug resistant
colonization to prevent infections in cancer patients and prevent community spread.
Finally, key databases with two different MLST methods may play a part in the dissimilarities
seen in sequence types. A comprehensive comparison of E.coli strains for both MLST methods
from the Achtman and Manning labs may help to decipher confusion of varying sequence types.
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